In comedy, the more you can surprise the audience by subverting their expectations, the better. There is nothing better than coming up with a brilliant set piece, something that writers and actors can ...

In medieval Denmark, people could pay for more prestigious graves closer to the church — a sign of wealth and status. But when researchers examined hundreds of skeletons, they discovered something ...

There are two kinds of Monty Python fans: casual rewatchers and the devotees who can quote every sketch from memory. If you're the latter, "Spamalot" is for you. Why it matters: The musical adapts ...

Scientists may have spotted a long-sought triplet superconductor — a material that can transmit both electricity and electron spin with zero resistance. That ability could dramatically stabilize ...

The biotech is developing a test to detect multiple cancers. However, a recent clinical trial did not produce the hoped-for results. The share price will likely remain low unless Grail has more ...

GRAIL Inc. (NASDAQ: GRAL) stock plunged during Friday’s premarket session following the announcement of results from the NHS-Galleri trial, which evaluated the effectiveness of the Galleri test in ...

Grail (GRAL) on Friday announced topline results from the landmark, randomized, controlled NHS-Galleri trial, which evaluated annual multi-cancer screening with the Galleri test in England's National ...

Just weeks after filing for FDA approval of its Galleri blood test for cancer screening, Grail has reported that a flagship trial of the technology in the UK failed to achieve its primary objective.

The trial was designed to demonstrate a statistically significant reduction in Stage III and Stage IV disease, but the primary endpoint wasn't met. It's possible that the follow-up data will prove ...

This article first appeared on GuruFocus. Grail (NASDAQ:GRAL) shares tumbled almost 50% on Friday after its three-year cancer screening trial missed its main goal, a setback for the blood test maker.

GRAIL reiterated its guidance from January, projecting "Galleri sales growth of 22% to 32% and cash burn for the full year of 2026 to be no more than $300 million." Management stated, "Our cash runway ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) trial of its Galleri test missed its primary endpoint. In top-line data ...